Immunic Inc (NASDAQ:IMUX) CEO Daniel Vitt spoke with Proactive's Stephen Gunnion about the company’s second-quarter results and provided a corporate update.
Vitt highlighted the execution of Immunic's main clinical studies, particularly focusing on multiple sclerosis (MS) programs with readouts expected next year and beyond. He also shared the appointment of Jason Tardio as chief operating officer and Simona Skerjanec's addition to the board of directors.
Discussing the company's financial health, Vitt noted, "We reported a cash position of $79 million at the end of the quarter, which is expected to sustain us into the third quarter of next year."
He detailed the progress of their MS studies, including the CALLIPER study set to read out next April and the Phase 3 ENSURE clinical program's futility analysis later this year, with full readout anticipated in 2026.
Vitt also announced an upcoming MS R&D day on September 10 in New York, aiming to showcase the unique opportunities of vidofludimus calcium, featuring notable neurologists Amit Bar-Or and Francesca Montarolo.